PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
PD-L1 negative	Melanoma	PD-L1 negative	Melanoma	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria nivolumab + ipilimumab Sensitive : C2	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria nivolumab + ipilimumab Sensitive : C2
PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	avelumab + VX15 Sensitive: C3 – Early Trials avelumab + VX15 Sensitive : C3	avelumab + VX15 Sensitive: C3 – Early Trials avelumab + VX15 Sensitive : C3
PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
PD-L1 negative	Urothelial Cancer	PD-L1 negative	Urothelial Cancer	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3
PD-L1 negative	Vulvar Cancer	PD-L1 negative	Vulvar Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3

PD-L1 negative

Associations